
Sign up to save your podcasts
Or
Eli Lilly shares rise after the drugmaker said on Friday that the FDA approved its weight-loss drug Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Xerox shares finish higher after the company struck a $1.5 billion deal to buy printer maker Lexmark. J.R. Whalen reports.
Programming note: Minute Briefing will release its next episode midday Tuesday.
Sign up for the WSJ's free What's News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
4.2
622622 ratings
Eli Lilly shares rise after the drugmaker said on Friday that the FDA approved its weight-loss drug Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Xerox shares finish higher after the company struck a $1.5 billion deal to buy printer maker Lexmark. J.R. Whalen reports.
Programming note: Minute Briefing will release its next episode midday Tuesday.
Sign up for the WSJ's free What's News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
1,630 Listeners
4,333 Listeners
1,754 Listeners
399 Listeners
452 Listeners
2,789 Listeners
1,434 Listeners
1,009 Listeners
1,285 Listeners
5,883 Listeners
1,528 Listeners
189 Listeners
1,317 Listeners
566 Listeners
151 Listeners
48 Listeners
75 Listeners
126 Listeners